About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

NCT01988831·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Geneva

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

patient over 18 y.o
Breslow index \> 1mm or any Breslow index with ulcerated primary lesion
Melanoma stage AJCC Ib, IIa, IIb, IIc, IIIa, IIIb or IIIc
Able to undergo outpatient treatment

You may not be if

No contra indication for betablockers as defined by the compendium
No clinical evidence of coagulopathy
No unstable angina pectoris
No AV-block II or III without pacemaker
No severe congestive heart failure
No untreated phaeochromocytoma
No severe bradycardia
No severe hypotension
No severe impairment of peripheral arterial circulation
No uncontrolled cardiac arrhythmia
No severe asthma or COPD
No uncontrolled diabetes mellitus
No Angioneurotic edema
No severe Aortic valve stenosis
No severe hypertrophic cardiomyopathy
No severe renal dysfunction
No patients on beta blockers by inclusion
No known adverse reaction to betablockers
No pregnant or lactating patients can be included
No melanoma stage AJCC IV by inclusion
No patients requiring a specific oncological treatment

The record

StatusSuspended

PhasePhase 2

Taking part450

StartedJun 2016

UpdatedMay 10, 2019

Conditions

Stages III Skin Melanoma Stages II Skin Melanoma Stage IB Skin Melanoma

Where1

Hôpital universitaire de Genève
Geneva, Canton of Geneva, Switzerland

Clareo Health | Efficacy of Propranolol Treatment to Prevent Melanoma Progression